) (ex 60%) Università di Ferrara (to GC). We present here the case of a 66 year old man with a severe bilateral community acquired pneumonia secondary to dissemination after an intravesical instillation of bacilllus Calmette-Guérin (BCG). Diagnosis was based on positive polymerase chain reaction (PCR) for mycobacterium tuberculosis complex in bronchoalveolar lavage and on the finding on transbronchial biopsy of non necrotising granulomas histopathologically similar to the granulomas found in bladder biopsies. These findings were confirmed using a validated real time PCR assay demonstrating the presence of the BCG genome in transbronchial and bladder biopsies.
ABSTRACT: Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case
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tazidime (2 grams thrice daily)] and intravenous methylprednisolone (40 mg once daily) were immediately started. On the third day after the admission the fever and the acute respiratory failure disappeared whereas the lung opacities were unmodified after a week of therapy. A fiberoptic bronchoscopy was performed showing no any sign of gross lesions in the central airways, a transbronchial biopsy sample was sent for pathological analysis and a broncho-alveolar lavage (BAL) for microbiology and cytopathological analysis was performed. A quantiFERON ®-TB GOLD ELISA was negative. Acid-fast stains and cultures (on sputum, urine and blood) were negative for bacteria, mycobacteria and fungi. After nine days the patient was moved to the Infectious Diseases ward for the presence in the BAL of positive polymerase chain reaction [AMPLICOR Mycobacterium tuberculosis Test (Roche Diagnostic Systems, USA)] for Mycobacterium tuberculosis complex whereas BAL culture was negative. An abdominal ultrasound examination was negative except for the presence of slight hepatomegaly and two benign cysts in the liver and kidney. Another chest radiography showed little changes in the pulmonary opacities. The pathological examination of the transbronchial biopsy revealed the presence of fibrosis and chronic interstitial inflammation with small non-necrotizing granulomas containing giant cells ( fig. 2A ). Acid-fast organisms were ab-sent. Similar lesions were observed in a bladder biopsy performed in the same patient two years before due to a suspicion that bladder cancer had recurred and attributed at the time to local inflammation secondary to the BCG therapy ( fig. 2B ). The presence of BCG genome in both transbronchial and bladder biopsies was confirmed using an in house validated real time PCR assay (fig. 2C, D) [1] . Standard anti-tubercular treatment was started per os with isoniazid (300 mg once daily); rifampin (600 mg once daily), ethambutol (1500 mg once daily) and pyrazinamide (1500 mg once daily) associated with a seven days course of intravenous methyl-prednisolone (20 mg once daily). Due to the occurrence of major hepatic side effects (ALT and γ-glutamyl-transpeptidase increase 3 times over the normal range), isoniazid, rifampin and pyrazinamide were discontinued and replaced by streptomycin (1 gram once daily intramuscularly) and levofloxacin (1 gram once daily per os) followed by progressive normalization of the serum level of these enzymes. After one month of therapy a new CT scan of the chest demonstrated the partial resolution of the lung opacities ( fig. 1C ). After 30 days by its introduction streptomycin was replaced with rifabutin (450 mg once daily per os), whereas ethambutol and levofloxacin were continued. A CT scan of the chest, performed after 5 months of therapy showed almost complete resolution of the lung opacities ( fig. 1D ). The patient completed 9 months of treatment overall, switching to two drugs (rifabutin and levofloxacin) only after 4 months from the beginning of the therapy. No sign of relapse were observed after the completion of treatment.
Discussion
We report here the fifteenth published case (on table) of community-acquired pneumonia caused by a disseminated BCG infection secondary to intravesical instillation of BCG immunotherapy for bladder cancer in adult patients. The appearance of the symptoms were strictly related to a minimal invasive procedure (bladder catheterization and instillation of BCG) complicated by gross hematuria. The onset of the radiological findings was also initially interpreted as pneumonia somehow related to the intervention. Interestingly, a AM-PLICOR-MBT test gave a positive result on BAL samples, and this triggered the isolation of the patient in an infectious diseases ward and the start of an anti-tuberculosis treatment. Infection by M. tuberculosis complex var. hominis could have been bona fide excluded because of the negativity of the Quantiferon TB test and by the appearance of the granulomatous lesions in the biopsies. Furthermore investigations demonstrated for the first time the presence in both transbronchial and bladder biopsies of the patient the presence of the BCG genome using a validated real time PCR assay based on the presence of a genomic region termed RD1 deleted (absent in all the other species of M. tuberculosis complex) in all the BCG strains [1] .
As previously reported acid fast stains are instead often negative in these cases as well as caseous necrosis is usually absent (table 1). The result of the in house method used in this report were controlled and their validity is strengthened by the fact that similar amplification products were obtained on the biopsies showing a similar pathological pattern.
The therapy of these disseminated BCG infections is mainly empirical, based on data from case series and expert opinion and includes a combination of antituberculous medications associated with systemic glucocorticoids (usually 40 mg of prednisone daily, gradually tapered over 4-6 weeks) in the most severe cases, as in our patient [2] . In vitro BCG is susceptible to most antituberculous drugs, including isoniazid, rifampin, ethambutol, fluoroquinolones, clarithromycin, some aminoglycosides, and doxycycline. Usually both isoniazid and rifampin are recommended as first therapeutic approach. However, if the patients treated with isoniazid and rifampin develop serious side effects or drug allergies, ethambutol and fluoroquinolones can be used as alternative treatments [14] . To prevent the dissemination of BCG after its intravesical therapy the administration of quinolones (such as ofloxacin and prulifloxacine) has been proven effective in small studies [16, 17] . This prophylactic antibiotic therapy has not been given to our patient after his last BCG instillation, despite him having described to the nurse a traumatic intravesical catheterisation, but he had taken for five days ciprofloxacin (500 mg bid) after the onset of fever, before being admitted to our hospital. There is a complete absence of studies on the immunopathogenesis of CAP secondary to disseminated BCG infection in adults. Individuals with impaired cell mediated immunity exhibit in- creased susceptibility to infections caused by poorly pathogenic mycobacteria (non-tuberculous mycobacteria and BCG), as well as salmonella species. However, these infections may also occur in a disseminated, fatal form, sometimes with familial distribution, in the absence of any recognised primary or secondary immunodeficiency. Genetic analysis of these families has recently defined mutations in many different genes of the interleukin 12 (IL-12)-dependent, interferon gamma (IFN-γ) pathway [18] . Interestingly all previous cases of disseminated BCG infection after intravesical BCG immunotherapy for bladder cancer described in the literature (table 1) occurred in males, suggesting, despite the concomitant 3:1 male-tofemale ratio for urothelial tumours, a potential influence of sex hormones in this susceptibility. In conclusion, CAP secondary to disseminated BCG infection is a rare complication of intravesical BCG immunotherapy for bladder cancer but additional studies are necessary to better understand its pathogenesis and to standardise the diagnosis and treatment.
